Polymorphisms and haplotypes in multidrug resistance 1 gene are not associated with chronic lymphocytic leukemia susceptibility and prognostic parameters of chronic lymphocytic leukemia in Chinese population

Leukemia and Lymphoma

Volumn 52, Issue 6, 2011, Pages 1003-1009

  Dong, Hua Jie ^a   Miao, Kou Rong ^a   Qiao, Chun ^a   Zhuang, Yun ^a   Shen, Wen Yi ^a   Hong, Ming ^a   Fan, Lei ^a   Liu, Peng ^a   Xu, Wei ^a   Li, Jian Yong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; haplotype; MDR1; prognostic marker; SNP

Indexed keywords

CD38 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ALGORITHM; ALLELE; ANTIGEN EXPRESSION; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CHINESE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HAPLOTYPE; HUMAN; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTIGENS, CD38; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMOSOME DELETION; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 79957526894     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.557454     Document Type: Article

References (28)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005;352:804-815.
2. Xu W, Li JY, Wu YJ, et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1071-1077. (Pubitemid 351514787)
3. Berkova A, Pavlistova L, Babicka L, et al. Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 2008;55:400-408.
4. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008;112:2024-2027.
5. Jamroziak K, Balcerczak E, Smolewski P, et al. MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. Pharmacol Rep 2006;58:720-728. (Pubitemid 44741691)
6. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A silent polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-528. (Pubitemid 46175758)
7. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478. (Pubitemid 30183327)
8. Sakaeda T. MDR1 genotype-related pharmacokinetics: fact or fiction? Drug Metab Pharmacokinet 2005;20:391-414.
9. Jamroziak K, Balcerczak E, Calka K, et al. Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ ABCB1) and risk of multiple myeloma. Leuk Res 2009;33: 332-335.
10. Consoli U, Santonocito A, Stagno F, et al. Multidrug resistance mechanisms in chronic lymphocytic leukaemia. Br J Haematol 2002;116:774-780. (Pubitemid 34226995)
11. Bosch F, Ferrer A, Lopez-Guillermo A, et al. Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. Br J Haematol 2002;119:976-984. (Pubitemid 35463822)
12. Tsimberidou AM, Kantarjian HM, Cortes J, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage- colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer 2003;97:1711-1720. (Pubitemid 36350714)
13. Leporrier M, Chevret S, Cazin B, et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001;98:2319-2325.
14. Robak T, Lech-Maranda E, Robak P. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 2010;10: 1529-1543.
15. Hallek M, Pflug N. State of the art treatment of chronic lymphocytic leukaemia. Blood Rev 2011;25:1-9.
16. Balcerczak E, Panczyk M, Piaskowski S, Pasz-Walczak G, Salagacka A, Mirowski M. ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis 2010;25:1167-1176.
17. Taheri M, Mahjoubi F, Omranipour R. Effect of MDR1 polymorphism on multidrug resistance expression in breast cancer patients. Genet Mol Res 2010;9:34-40.
18. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. J Int Bioethique 2004;15:124-129.
19. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111: 5446-5456.
20. Ni LN, Li JY, Miao KR, et al. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia. Med Oncol 2010 Mar 4. [Epub ahead of print]
21. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-989. (Pubitemid 32289743)
22. Kimchi-Sarfaty C, Marple AH, Shinar S, et al. Ethnicityrelated polymorphisms and haplotypes in the human ABCB1 gene. Pharmacogenomics 2007;8:29-39. (Pubitemid 46157755)
23. Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol 2004;72:314-321. (Pubitemid 38520728)
24. Zhang Y, Jiang XH, Hu YQ, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 600 mg valacyclovir in healthy Chinese Han ethnic males. Br J Clin Pharmacol 2008;66:247-254.
25. Penna G, Allegra A, Alonci A, et al. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. Med Oncol 2010 May 22. [Epub ahead of print]
26. Guillaume N, Gouilleux-Gruart V, Claisse JF, et al. Multidrug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2007;48: 1556-1560. (Pubitemid 47272806)
27. Hoellein A, Decker T, Bogner C, et al. Expression of multidrug resistance-associated ABC transporters in B-CLL is independent of ZAP70 status. J Cancer Res Clin Oncol 2010;136:403-410.
28. Maggini V, Buda G, Martino A, et al. MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 2008;18:383-389. (Pubitemid 351535939)